Research News
View articles by month and year
11–20 of 20 articles
-
Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
Early results suggest that a combination of four medicines given BEFORE surgery to treat HER2-positive, early-stage breast cancer may be a good way to weaken and destroy breast cancer cells.
-
Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer
Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.
-
FDA Approves Tykerb-Femara Combo to Treat Advanced-Stage Disease
The FDA has approved the combination of Tykerb and Femara to treat post-menopausal women diagnosed with hormone-receptor-positive, HER2-positive advanced-stage breast cancer.
-
Herceptin Plus Tykerb Improves Survival for Women with Metastatic HER2-Positive Breast Cancer
HER2-positive, metastatic breast cancer that grows while being treated with Herceptin seems to benefit from adding Tykerb to the Herceptin rather than switching from Herceptin to Tykerb.
-
Tykerb May Help Treat HER2-Positive Inflammatory Breast Cancer
Tykerb (chemical name: lapatanib) may be effective against HER2-positive inflammatory breast cancer after other treatments don't work any more.
-
Femara and Tykerb Combo Better Than Femara Alone for Metastatic Hormone-Receptor-Positive, HER2-Positive Cancers
A new study shows that treating hormone-receptor-positive, HER2-positive metastatic breast cancer with the combination of Femara and Tykerb offers more benefits than Femara alone.
-
Experimental HER2 Vaccine Shows Promise
A very early study done in mice shows promise for a vaccine against HER2-positive cancer cells.
-
Adding Tykerb to Herceptin Helps if Metastatic Breast Cancer Grows
Women diagnosed with HER2-positive metastatic breast cancer that either came back or progressed while getting Herceptin (chemical name: tastuzumab) benefited from adding Tykerb (chemical name: lapatanib) to the treatment plan instead of switching from Herceptin to Tykerb.
-
New Study Compares Tykerb and Herceptin
A new clinical trial will try to find out whether using Herceptin (chemical name: trastuzumab) alone, Tykerb (chemical name: lapatinib) alone, or both medicines together is better for women diagnosed with stage I or stage II HER2-positive breast cancer.
-
Tykerb and Xeloda Effective on Breast Cancer in Brain
A small study shows that Tykerb (chemical name: lapatinib) combined with Xeloda (chemical name: capecitabine) can stop the growth of HER2-positive breast cancer that has spread to the brain.
11–20 of 20 articles
